Fat mass and obesity gene and cognitive decline
The Atherosclerosis Risk in Communities Study
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received February 5, 2012
- Accepted August 15, 2012
- First Published November 7, 2012.
Article Versions
- Previous version (November 7, 2012 - 13:01).
- You are viewing the most recent version of this article.
Author Disclosures
- Jan Bressler, PhD,
- Myriam Fornage, PhD,
- Ellen W. Demerath, PhD,
- David S. Knopman, MD,
- Keri L. Monda, PhD,
- Kari E. North, PhD,
- Alan Penman, PhD,
- Thomas H. Mosley, PhD and
- Eric Boerwinkle, PhD
- Jan Bressler, PhD,
NONE
NONE
Dr. Michael Andreeff (spouse) received funding for travel from Roche Pharmaceuticals; and an honorarium from Genzyme.
Spouse serves on the editorial board of Annals of Hematology (1995-present); Leukemia (2008-present); and Molecular Cancer Therapeutics (2012).
Spouse holds a patent for a drug used in cancer treatment from Reata Pharmaceuticals.
NONE
NONE
Spouse receives consulting fees from Reata Pharmaceuticals (2004-present).
NONE
NONE
NONE
Spouse received an unrestricted gift for research from Karyopharm (2011).
Funded as co-investigator by NIH grant U01 HL096917 (2010-2012); Spouse is funded by NIH grants P01 CA55164 (2007-present); and R21 CA143805 (2010-present) as principal investigator; by NIH grants RC1 CA146381 (2009-present) and P50 CA12700 (2008-present) as co-investigator; by NIH grants P01 CA049639 (2010-present); P50 CA100632 (2008-present); P50 CA083639 (2010-present); and P50 CA136411 (2009-present) as project leader; by NIH grant P30 CA0166672 (2008-present) as core leader; and by FDA grant R01 FD003733 (2009-present) as principal investigator
NONE
NONE
NONE
Spouse received license fee payments for drug used in cancer treatment from Reata Pharmaceuticals.
NONE
NONE
NONE
NONE
- Myriam Fornage, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ellen W. Demerath, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
COSMED, INC
NIH, N01 HC55019, Co-I, 2010-2016, NIH, DK053685, PI, 2007-2012, NIH, N01 HV048048, Co-I, 2008-2013, NIH, R01 HD012252 (Subcontract PI) 2010-2016, NIH, U01 HL103621, Co-I, 2010 - 2017
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David S. Knopman, MD,
Lilly Pharmaceuticals, Data Safety Monitoring Board
NONE
(1) Lecture, University of Zurich, March 2010; (2) Lecture, University of Montana, October 2010; (3) Lecture, University of Toronto, March 2012
Neurology, Deputy Editor
NONE
NONE
NONE
(1) Janssen Alzheimer Immunotherapy program 3/29/11: honorarium paid to my institution; (2) Merck Alzheimer program 11/5/11 paid to my institution.
NONE
NONE
NONE
(1) Janssen for Alzheimer clinical trial, (2) Forest Laboratories for clinical trial in FTLD with memantine, (3) Baxter Laboratories for Alzheimer Clinical trial
NIH: R01-AG11378 ongoing, P50-AG 16574 (Mayo Alzheimer's Disease Research Center) ongoing, U01 AG 06786 (Mayo Alzheimer Disease Patient Registry) ongoing. NIH R01 AG32306 FTD Neuro-imaging;Initiative. 1U01HL096917-01 ARIC Dementia Study.AG 037551 Chronic Kidney Disease and Cognitive functioning.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Keri L. Monda, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH, Research Assistant Professor salary, 2011
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kari E. North, PhD,
NONE
NONE
NONE
Guest Editor for Circulation, Editor for Frontiers Genetic Epidemiology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alan Penman, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1. NIH/NHLBI N01-HC55021 - Mosley (PI) 02/01/2006 - 11/14/2016, Atherosclerosis Risk in Communities Study (ARIC), Role: Biostatistician (Jackson Field Center), 2. NIH/NHLBI/NINDS/NEI U01-HL096917 (Mosley) 07/07/2010 - 04/30/2014, ARIC Neurocognitive Study (ARIC NCS), Role: Biostatistician (Jackson Field Center), 3. UMC/VA CLIN-001-10F - Burton (PI) 01/01/2012 - 06/30/2014, Interaction of HSV-2 in Veterans with Chronic Hepatitis C Co-Infection, Role: Biostatistician
NONE
UMMC #58741 - Sobrin (PI) 10/01/2010-09/30/2013, Friends of the Massachusetts Eye and Ear Infirmary Genetics of Proliferative Diabetic Retinopathy in African-Americans, Role: Jackson PI
NONE
NONE
NONE
NONE
NONE
NONE
- Thomas H. Mosley, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eric Boerwinkle, PhD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Boerwinkle: ACTIVE 5 RC2 HL 102419-02 (Boerwinkle) 09/30/2009 - 07/31/2012, 1.20 calendar NIH/NHLBI $13,687,235 Building on GWAS for NHLBI-diseases: the CHARGE Consortium This project is to re-sequence selected regions identified in GWAS of major CVD traits. 5 N01HC 55016-40-0-1 (Ballantyne) 11/15/2010 - 10/31/16, 0.60 calendar NIH/NHLBI $$384,834 Atherosclerosis Risk in Communities (ARIC) Study This project will carry-out analyze and publish targeted genetic and gene-environment interaction studies on coronary heart disease, congestive heart failure, endothelial function and lung function and provide expert guidance and leadership to the ARIC Steering Committee on technical, analytical and ethical issues related to large scale genomic research. 5 U01 HG 004803-04 (Heiss) 07/17/2008 - 05/31/2013, 0.36 calendar NIH/NHGRI-University of North Carolina, Chapel Hill $348,258 Genetic Epidemiology of Causal Variants Across the Life Course To accelerate the understanding of the role and population impact of putative causal genetic variants related to complex diseases. 5 RC2 HG005697 (Hixson) 09/30/2009 - 08/31/2012 0.60 calendar NIH/NHLBI Next-Generation Medical Resequencing of Gout Disease Genes in the ARIC Cohort This project will use next-generation sequencing technology to resequence candidate genes in gout cases and controls from the ARIC cohort to identify genetic variants that influence gout and uric acid levels.5 R01 HL 072810-09 (Boerwinkle) 06/01/2003 - 02/28/2013 1.20 calendar NIH/NHLBI $694,917 Modeling DNA Diversity in Reverse Cholesterol Transport The goal of this Multi-Institutional Research Project grant is to identify the genes influencing HDL-C in the population-at-large. This research not only considers the individual effects of variation in each gene, but their interactions with other genes and with the environment. We also ask if these genetic variations predict CHD beyond the traditional risk factors, such as smoking and hypertension. 1 U01 HL 096917-02 (Mosley) 07/07/2010 - 06/30/2013 0.60 calendar NIH/NHLBI/NINDS/NEI $244,613ARIC Neurocognitive Study (ARIC NCS) ARIC NCS will identify risk factors for dementia, mild cognitive impairment, and cognitive decline in the biracial longitudinal ARIC cohort study of the natural history of atherosclerosis. 1 R01 HL 106034-02 (Xiong) 01/10/2011 - 12/31/2014 0.60 calendar NIH/NHLBI $376,093 Statistical Methods for Finding Missing Heritability The goal of this proposal is to use genome continuum model as a general principle, data reduction, functional data analysis techniques, and systems biology tools for developing novel and powerful statistical methods for detection interaction between genes (or pathways) with both common and rare variants and environments with both discrete and continuous measurements, and carry out genome-wide gene-environment interaction. 2 U01 GM 074492-08 (Johnson) 08/03/2005 - 07/31/2015 0.6 calendar NIH/NIGMS $337,485Pharmacogenomic Evaluation of Antihypertensive Responses We will provide genetic analysis of all study samples for the genome spanning studies. 1 U54 HG006542-01 (Valle) 12/05/11 - 11/30/15 0.6 calendar NIH Baylor-Johns Hopkins Center for Mendelian Genetics Collaboration with Drs. Valle and Lupski to identify genes leading to targeted Mendelian disorders. Analyzing data to establish genotype-phenotype associations which will also include formal statistical analyses of clustering of variants within a gene or gene region. 2 U54 HG003273-09 (Gibbs) 11/01/11 - 10/31/2012 2.4 calendar NIH $235,162 The Human Genome Sequencing Center Active close collaboration on the statistical design and analysis of projects, particular population studies.Vicki Huff (Spouse): U10 CA09843-07S6 Huff (Co-PI) 09/01/2009- 08/31/2012 NIH/NCI $20,839 annual direct costs TARGET: Wilms Tumor, P. Adamson, PI 0.6 months The major goal of this project is to use genomic data to identify genes/pathways that can be therapeutically targeted in Wilms tumor patients RP100329 Huff (PI) 3/1/2010 - 2/28/2013 CPRIT (Cancer Prevention & Research Institute of Texas) $186,104 annual direct costs Next Generation Genomic Sequence Identification of the 19q 1.8 months Familial Wilms Tumor Predisposition Gene The major goal of this project is to identify the 19q familial WT gene using Next-Gen DNA sequencing data. RP110324 Huff (PI) 1/1/2011 - 12/31/2014 CPRIT (Cancer Prevention & Research Institute of Texas) $351,165 annual direct costs Impact of differentiation status on tumorigenesis 3.6 months The major goal of this project is to determine whether targeting gene alterations to different cellular compartments in the developing kidney will result in Wilms tumors that exhibit distinctive molecular and clinical characteristics. CA98543 09 Huff (Chair, COG Renal Tumor Biol Comm) 3/1/2012 - 2/28/2013 NIH/NCI Children's Oncology Group (COG). P. Adamson, PI $5,017 annual direct costs 0.3 months The goal of this project is to develop more efficacious therapies for Wilms tumor patients. My role is to head up the Renal Tumor Biology Committee that oversees and guides research projects that provide biological data to further this goal. CA016672 DePinho (PI) 9/14/1998 - 6/30/2013 NIH/NCI Huff, Director $283,568 annual direct costs Cancer Center Support Grant-Sequence & Microarray Facility 1.2 months The goal of this project is to provide MDACC investigators with state-of-the-art technology for DNA and RNA analyses. CA054498 Huff, PI, Subcontract 9/1/2012 - 8/31/2017 NIH/NCI Breslow (PI) $14,882 annual direct costs Late Effects of Treatment in Wilms Tumor Survivors 0.3 months The goal of this project is to assess the long-term consequences of treatment in survivors of WIlms tumor, with special reference to the role of germline WT1 mutations.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Human Genetics Center (J.B., M.F., E.B.), School of Public Health, University of Texas Health Science Center at Houston; Brown Foundation Institute of Molecular Medicine (M.F., E.B.), University of Texas Health Science Center at Houston; Division of Epidemiology and Community Health (E.W.D.), School of Public Health, University of Minnesota, Minneapolis; Department of Neurology (D.S.K.), Mayo Clinic, Rochester, MN; Department of Epidemiology (K.L.M., K.E.N.), Gillings School of Global Public Health, University of North Carolina, Chapel Hill; Carolina Center for Genome Sciences (K.E.N.), School of Medicine, University of North Carolina, Chapel Hill; and Department of Internal Medicine (A.P., T.H.M.), Division of Geriatrics, University of Mississippi Medical Center, Jackson.
- Correspondence to Eric Boerwinkle: Eric.Boerwinkle{at}uth.tmc.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Association of hospitalization with long-term cognitive and brain MRI changes in the ARIC cohortCharles H. Brown IV, A. Richey Sharrett, Josef Coresh et al.Neurology, March 11, 2015 -
Articles
Cognitive function predicts first-time stroke and heart diseaseJacob S. Elkins, David S. Knopman, Kristine Yaffe et al.Neurology, May 23, 2005 -
Articles
APOE genotype and cognitive decline in a middle-aged cohortC. K. Blair, A. R. Folsom, D. S. Knopman et al.Neurology, January 24, 2005 -
Articles
Cerebral MRI findings and cognitive functioningThe Atherosclerosis Risk in Communities StudyT. H. Mosley, Jr, D. S. Knopman, D. J. Catellier et al.Neurology, June 27, 2005